This study represents the first systematic review and meta-analysis to thoroughly evaluate and quantify the efficacy and safety of both SYK and BTK inhibitors in comparison to placebo for treating adult ITP. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.